+1 Recommend
1 collections
      • Record: found
      • Abstract: found
      • Article: found

      Plasma 3α-Androstanediol Glucuronide in Normal Children and in Congenital Adrenal Hyperplasia due to 21 -Hydroxylase Deficiency

      Read this article at

          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.


          Monitoring therapy for congenital adrenal hyperplasia (CAH) due to 21-hydroxylase is difficult, although plasma determinations of 17α-hydroxyprogesterone (170HP), Δ4-androstenedione (Δ4A) and testosterone are helpful. We have studied the usefulness of monitoring plasma 3α-androstanediol glucuronide (3α-AG) in a group of 24 CAH patients aged from birth to 18 years. For comparison, normal values for age and pubertal stage were determined in a control group of 115 girls and 118 boys. Mean plasma levels were higher during the first year of life, decreased to a nadir between 1 and 4 years, and increased steadily thereafter; there was also a significant increase with pubertal stage. In 24 pairs of blood samples obtained at the time of venopuncture and 2 h after, 3α-AG levels did not change (p > 0.05) demonstrating that 3α-AG levels were not affected by stress. In the patients with CAH, positive correlations between plasma 3α-AG and Δ4A (females, r = 0.73; males, r = 0.98), 170HP (females, r = 0.58; males, r = 0.84) and testosterone (females, r = 0.83; males, r = 0.97) were observed. Concordance between 3α-AG and Δ4A was observed in 90% of all samples, and in 91 % between 3α-AG and testosterone. Our study demonstrates that 3α-AG is a valid marker of control and its determination appears to be a reliable tool to monitor CAH.

          Related collections

          Author and article information

          Hormone Research in Paediatrics
          S. Karger AG
          10 December 2008
          : 48
          : 1
          : 35-40
          Division of Biology of Growth and Reproduction, Department of Pediatrics, Geneva Cantonal Hospital, Geneva, Switzerland
          185366 Horm Res 1997;48:35–40
          © 1997 S. Karger AG, Basel

          Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

          Page count
          Pages: 6
          Original Paper


          Comment on this article